Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label Study of CTX-471 in Patients With NCAM Positive Tumors

NCT07684170 is registered in ClinicalTrials.gov with Compass Therapeutics as lead sponsor.

NCT NCT07684170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07684170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label Study of CTX-471 in Patients With NCAM Positive Tumors
Lead sponsor
Compass Therapeutics
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
September 30, 2029
Enrollment
58 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine carcinomas, neuroendocrine neoplasm, neuroendocrine tumors